Literature DB >> 8220889

Dissociation of the anti-ischaemic effects of cloricromene from its anti-platelet activity.

P S Lidbury1, R Cirillo, J R Vane.   

Abstract

1. Cloricromene is a non-anticoagulant coumarin derivative with anti-platelet and anti-leukocyte properties, which has beneficial effects in various models of ischaemia and shock. 2. We have assessed the effects of cloricromene on (a) ex vivo platelet aggregation, and (b) infarct size using a model of myocardial ischaemia in the anaesthetized rabbit. 3. Cloricromene (1-1000 micrograms kg-1 min-1 for 15 min) induced a dose-dependent inhibition of ex vivo platelet aggregation, causing only a minimal increase in heart rate and no change in mean arterial blood pressure. The inhibitory activity was considerably stronger when platelet aggregation was induced by collagen than by ADP. 4. Cloricromene inhibited ex vivo platelet aggregation in rabbits pretreated with indomethacin (5 mg kg-1) and this inhibition persisted for 30-60 min. 5. The model of myocardial ischaemia involved 1 h occlusion of the first antero-lateral branch of the left coronary artery followed by 2 h of reperfusion. Infusion of cloricromene (30 or 300 micrograms kg-1 min-1), ibuprofen (80 micrograms kg-1 min-1) or vehicle began 15 min prior to occlusion, and continued throughout the experiment. 6. While area at risk was similar for all groups studied, cloricromene (30 or 300 micrograms kg-1 min-1) or ibuprofen caused a reduction in infarct size, and decreased myeloperoxidase activity in the tissue of the infarcted myocardium. 7. Cloricromene at 300 micrograms kg-1 min-1 also reduced the occlusion-induced elevation of the ST-segment of the rabbit electrocardiogram, and inhibited platelet aggregation ex vivo. Ibuprofen or cloricromene at 30 fg kg-1 min-1 had no effect on either the ST-elevation or platelet reactivity.8. Thus, cloricromene exhibits a cardioprotective activity via an inhibition of leukocyte infiltration, in the presence (300 microg kg-l min-1) or absence (30 microg kg-1 min-1) of inhibition of platelet activity ex vivo.The anti-aggregatory activity of cloricromene acts via a mechanism that is either different from, or in addition to, inhibition of cyclo-oxygenase, and is of long duration.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8220889      PMCID: PMC2176012          DOI: 10.1111/j.1476-5381.1993.tb13805.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  27 in total

Review 1.  Mechanisms and therapy of myocardial reperfusion injury.

Authors:  M B Forman; R Virmani; D W Puett
Journal:  Circulation       Date:  1990-03       Impact factor: 29.690

Review 2.  Endothelial, platelet and leukocyte interactions in ischemic heart disease: insights into potential mechanisms and their clinical relevance.

Authors:  J L Dinerman; J L Mehta
Journal:  J Am Coll Cardiol       Date:  1990-07       Impact factor: 24.094

Review 3.  Granulocytes as active participants in acute myocardial ischemia and infarction.

Authors:  G W Schmid-Schönbein; R L Engler
Journal:  Am J Cardiovasc Pathol       Date:  1987-01

4.  Action of AD6 (8-monochloro-3-beta-diethylaminoethyl-4-methyl-7-ethoxycarbonylmet hox y coumarin) on human platelets in vitro.

Authors:  M Prosdocimi; A Zatta; A Gorio; A Zanetti; E Dejana
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-03       Impact factor: 3.000

5.  Protective effect of cloricromene, a coumarine derivative, in hypovolemic hemorrhagic shock in the rat.

Authors:  R Sturniolo; F Squadrito; G M Campo; R Vinci; A Calatroni; M Prosdocimi; A P Caputi
Journal:  J Cardiovasc Pharmacol       Date:  1991-02       Impact factor: 3.105

6.  In vitro inhibition of human polymorphonuclear cell function by cloricromene.

Authors:  F Bertocchi; F Breviario; P Proserpio; J M Wang; P Ghezzi; R A Travagli; M Prosdocimi; E Dejana
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-06       Impact factor: 3.000

7.  Cardioprotective and endothelial protective effects of [Ala-IL8]77 in a rabbit model of myocardial ischaemia and reperfusion.

Authors:  A M Lefer; G Johnson; X L Ma; P S Tsao; G R Thomas
Journal:  Br J Pharmacol       Date:  1991-05       Impact factor: 8.739

8.  Defibrotide reduces infarct size in a rabbit model of experimental myocardial ischaemia and reperfusion.

Authors:  C Thiemermann; G R Thomas; J R Vane
Journal:  Br J Pharmacol       Date:  1989-06       Impact factor: 8.739

9.  Xanthine oxidase is not a source of free radicals in the ischemic rabbit heart.

Authors:  J M Downey; T Miura; L J Eddy; D E Chambers; T Mellert; D J Hearse; D M Yellon
Journal:  J Mol Cell Cardiol       Date:  1987-11       Impact factor: 5.000

10.  Cloricromene improves survival rate and peritoneal macrophage function in splanchnic artery occlusion shock in rats.

Authors:  R Sturniolo; F Squadrito; D Altavilla; G R Trimarchi; M Prosdocimi; A P Caputi
Journal:  Circ Shock       Date:  1989-07
View more
  4 in total

1.  The effects of the endothelin ETA receptor antagonist, FR 139317, on infarct size in a rabbit model of acute myocardial ischaemia and reperfusion.

Authors:  L McMurdo; C Thiemermann; J R Vane
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

2.  Cloricromene in endotoxemia: role of NF-kappaB.

Authors:  A Ianaro; P Maffia; G Grassia; P Di Meglio; R Sorrentino; R d'Emmanuele di Villa Bianca; M Di Rosa; A Ialenti
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-07-30       Impact factor: 3.000

3.  Inhibition of PAF synthesis by stimulated human polymorphonuclear leucocytes with cloricromene, an inhibitor of phospholipase A2 activation.

Authors:  E Ribaldi; A M Mezzasoma; E Francescangeli; M Prosdocimi; G G Nenci; G Goracci; P Gresele
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

4.  Multiple actions of the coumarine derivative cloricromene and its protective effects on ischemic brain injury.

Authors:  G Calapai; F Squadrito; A Rizzo; M C Marciano; G M Campo; A P Caputi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-02       Impact factor: 3.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.